Dr. Le’s expertise are in the development of new immunotherapy strategies for invention and treatment of drug addiction and new mucosal adjuvant approach in treatment of chronic disease.
In order to contribute to the cessation of smoking to reduce health risks and improve environmental conditions, Dr. Le proposes a novel mucosal nicotine vaccine approach that can be delivered through the nose and skin routes. This strategy aims to block nicotine inhaled from cigarettes at the lung tissue before it reaches the bloodstream because it not only induces IgG in the blood, but also produces IgA, which will offer another line of defense for the brain.
The new mucosal vaccine is produced in a freeze-dried formulation that facilitates vaccine storage and transport and it offers an affordable, pain-free and easy delivery to patients. This platform is not only ideal for tobacco addiction, but can also be deployed to other drug addiction treatment applications, such as cocaine, methamphetamine and heroin treatment.
Chronic diseases, including diabetes, obesity, and heart disease, have high potential impacts not only in developed countries, but also in low and middle income countries. More than 35 million people worldwide died from chronic diseases every year. Dr. Le’s research also investigates new mucosal adjuvant approach in treatment of chronic disease. There is promising proof to use immunodrugs to reduce blood pressure in hypertensive patients or blood sugar levels in patients with type 2 diabetes. We are developing the new bacteria-derived particles/self-assembled lipid peptides as an adjuvant system for non-injection immunotherapy to prevent or treat the chronic disease (LPS target).